Domača stranNTLA • NASDAQ
add
Intellia Therapeutics Inc
Prejšnji trg. dan.
12,02 $
Dnevni razpon
9,93 $ - 11,43 $
Letni razpon
9,93 $ - 34,87 $
Tržna kapitalizacija
1,04 mrd. USD
Povprečni obseg
2,36 mio.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 9,11 mio. | −24,02 % |
Stroški poslovanja | 30,50 mio. | 3,73 % |
Čisti dohodek | −135,71 mio. | −11,04 % |
Čista dobičkovnost prihodkov | −1,49 tis. | −46,15 % |
Earnings per share | −1,34 | 2,90 % |
EBITDA | −142,16 mio. | −10,36 % |
Efektivna davčna stopnja | — | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 658,11 mio. | −23,01 % |
Skupna sredstva | 1,17 mrd. | −5,63 % |
Skupne obveznosti | 210,74 mio. | 2,33 % |
Celoten lastniški kapital | 962,62 mio. | — |
Shares outstanding | 101,85 mio. | — |
Razmerje P/B | 1,27 | — |
Donosnost sredstev | −30,61 % | — |
Donosnost kapitala | −33,80 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −135,71 mio. | −11,04 % |
Denar iz dejavnosti | −84,84 mio. | 16,32 % |
Denar iz naložb | −7,71 mio. | −109,70 % |
Denar iz financiranja | 82,19 mio. | 330,28 % |
Neto sprememba denarnih sredstev | −10,35 mio. | −272,58 % |
Prost denarni tok | −35,80 mio. | 44,08 % |
Vizitka
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
Generalni direktor
Datum ustanovitve
2014
Sedež organizacije
Spletno mesto
Zaposleni
526
